Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.
Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.
San Diego-based Batu Biologics Inc., is taking a more inventive approach. Batu’s new cancer vaccine, ValloVax™, is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission.
A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.
Batu Biologics is pleased to announce the release of the 2014 Shareholder Letter discussing the year-end progress in the development of its anti-angiogenic lung cancer vaccine, ValloVax.